$COLL SEC Filings

Filed On	Filing
19 Oct 2026	8-K: Termination of a Material Definitive Agreement As previously disclosed, Collegium Pharmaceutical, Inc. (the “Company”) is party to a License Agreement (U.S.), dated as of January 13, 2015, with Grünenthal GmbH (“Grünenthal”) (as amended, the “Grünenthal License”) which the Company as...
08 Oct 2026	SCHEDULE 13G/A
30 Sep 2026	144
24 Aug 2026	SCHEDULE 13G
14 Aug 2026	SCHEDULE 13G
13 Aug 2026	8-K: Other Events
06 Aug 2026	10-Q
06 Aug 2026	8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
05 Aug 2026	SCHEDULE 13G
31 Jul 2026	SCHEDULE 13G
17 Jul 2026	144
15 Jul 2026	144
30 Jun 2026	8-K/A: Financial Statements and Exhibits On May 12, 2026, Collegium Pharmaceutical, Inc. (the “Company” or “Collegium”) completed the previously announced acquisition (the “Closing”) of (i) all of the issued and outstanding limited liability interests of GPC Commave Holding, LL...
10 Jun 2026	Form 4: Santini Gino, Director Received 8,700 shares by exercise or conversion ($143K)
01 Jun 2026	FORM S-8
01 Jun 2026	FORM S-8
20 May 2026	Form 4: Freund John Gordon, Director Sold 20 shares ($681)
18 May 2026	Form 4: Paya Carlos V, Director Received 8,741 shares as a grant or award
18 May 2026	Form 4: Lurker Nancy, Director Received 8,741 shares as a grant or award
18 May 2026	Form 4: Freund John Gordon, Director Received 8,741 shares as a grant or award · Received 8,700 shares by exercise or conversion ($143K) · Sold 4,127 shares ($143K)

Comments